STOCK TITAN

Omega Therapeutics Inc - OMGA STOCK NEWS

Welcome to our dedicated news page for Omega Therapeutics (Ticker: OMGA), a resource for investors and traders seeking the latest updates and insights on Omega Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Omega Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Omega Therapeutics's position in the market.

Rhea-AI Summary
Omega Therapeutics to present new preclinical data on epigenomic controllers for liver diseases at AASLD 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.77%
Tags
none
-
Rhea-AI Summary
Omega Therapeutics to present new preclinical data supporting potential of OTX-2101 for NSCLC treatment at AACR-NCI-EORTC conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.14%
Tags
conferences clinical trial
-
Rhea-AI Summary
Omega Therapeutics announces encouraging preliminary data from Phase 1/2 MYCHELANGELO I study on OTX-2002 in patients with hepatocellular carcinoma (HCC) and other solid tumors associated with the c-MYC gene.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.17%
Tags
Rhea-AI Summary
Omega Therapeutics, Inc. (Nasdaq: OMGA) will host a conference call and webcast to discuss preliminary clinical data from the ongoing Phase 1/2 MYCHELANGELO™ I trial of OTX-2002 on September 26, 2023. The webcast will feature a moderated discussion with Gerard Evan, Ph.D. The archived webcast will be available on Omega’s website for approximately 90 days following the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.17%
Tags
conferences clinical trial
-
Rhea-AI Summary
Omega Therapeutics, Inc. announces participation in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
conferences
-
Rhea-AI Summary
Chris Schade appointed as Chairman of the Board, Michelle C. Werner joins the Board of Directors. Omega Therapeutics well positioned for growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.29%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.25%
Tags
management
-
Rhea-AI Summary
Omega Therapeutics, Inc. (Nasdaq: OMGA) will participate in two investor conferences, Jefferies Healthcare Conference and Goldman Sachs 44th Annual Global Healthcare Conference. Live webcasts and archived replays will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.14%
Tags
conferences
Omega Therapeutics Inc

Nasdaq:OMGA

OMGA Rankings

OMGA Stock Data

147.54M
21.36M
1.97%
94.48%
7.32%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Cambridge

About OMGA

omega therapeutics™ is a preclinical stage genomic medicine enterprise transforming medicine and patient care through precision genomic control. the company’s platform is focused on selectively directing the human genome to treat and cure disease by precisely controlling genomic expression without changing nucleic acid sequences. we are developing precision therapeutics for a range of disease indications including rare genetic diseases, immunology, inflammation, metabolic diseases and oncology. # transformativemedicines #pioneeringmedicines